Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

mitomycin

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

DNA synthesis inhibitor

Related drugs:

‹

captisol-enabled melphalan (0)

cisplatin (330)

gemcitabine (181)

temozolomide (114)

cytarabine (99)

oxaliplatin (57)

dacarbazine (22)

cytarabine/daunorubicin liposomal formulation (19)

clofarabine (16)

carmustine (14)

temozolomide gel (7)

fludarabine IV (6)

hydroxyurea (3)

mercaptopurine (3)

fotemustine (2)

streptozocin (2)

fludarabine oral (2)

thioguanine (2)

fosgemcitabine palabenamide (1)

asparagine cytarabine conjugate (1)

gemcitabine-releasing intravesical system (1)

mitomycin urothelial gel (1)

melphalan hepatic delivery system (1)

liposomal cisplatin (0)

pegylated liposomal mitomycin-c prodrug (0)

mercaptopurine oral suspension (0)

gemcitabine with RenovoCath (0)

cytarabine ocfosfate (0)

mitomycin intravesicular (0)

captisol-enabled melphalan (0)

›

No biomarker	Penile Cancer	No biomarker	Penile Cancer	5-fluorouracil + mitomycin Sensitive: A2 - Guideline 5-fluorouracil + mitomycin Sensitive : A2	5-fluorouracil + mitomycin Sensitive: A2 - Guideline 5-fluorouracil + mitomycin Sensitive : A2
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	mitomycin Sensitive: A2 - Guideline mitomycin Sensitive : A2	mitomycin Sensitive: A2 - Guideline mitomycin Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	5-fluorouracil + mitomycin Sensitive: A2 - Guideline 5-fluorouracil + mitomycin Sensitive : A2	5-fluorouracil + mitomycin Sensitive: A2 - Guideline 5-fluorouracil + mitomycin Sensitive : A2
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	mitomycin Resistant: A2 - Guideline mitomycin Resistant : A2	mitomycin Resistant: A2 - Guideline mitomycin Resistant : A2
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	capecitabine + mitomycin Sensitive: A2 - Guideline capecitabine + mitomycin Sensitive : A2	capecitabine + mitomycin Sensitive: A2 - Guideline capecitabine + mitomycin Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	capecitabine + mitomycin Sensitive: A2 - Guideline capecitabine + mitomycin Sensitive : A2	capecitabine + mitomycin Sensitive: A2 - Guideline capecitabine + mitomycin Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	capecitabine + mitomycin Sensitive: A2 - Guideline capecitabine + mitomycin Sensitive : A2	capecitabine + mitomycin Sensitive: A2 - Guideline capecitabine + mitomycin Sensitive : A2
TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q)	Mesothelioma	TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q)	Mesothelioma	cisplatin + carboplatin + pemetrexed + mitomycin Resistant: C4 – Case Studies cisplatin + carboplatin + pemetrexed + mitomycin Resistant : C4	cisplatin + carboplatin + pemetrexed + mitomycin Resistant: C4 – Case Studies cisplatin + carboplatin + pemetrexed + mitomycin Resistant : C4
MLANA expression + SOX10 expression	Ocular Melanoma	MLANA expression + SOX10 expression	Ocular Melanoma	mitomycin Sensitive: C4 – Case Studies mitomycin Sensitive : C4	mitomycin Sensitive: C4 – Case Studies mitomycin Sensitive : C4
REST signature	Glioblastoma	REST signature	Glioblastoma	mitomycin Sensitive: D – Preclinical mitomycin Sensitive : D	mitomycin Sensitive: D – Preclinical mitomycin Sensitive : D